Dydrogesterone – a promising asset for luteal phase support in infertility treatment

A randomized, controlled, comparative study conducted from 2022-2023 at Gandhi Hospital evaluated the efficacy of oral dydrogesterone versus oral sustained-release micronized hydroxyprogesterone for luteal phase support.

This study enrolled 200 women aged 18-40 years who were attending the infertility outpatient department.

The findings revealed that oral dydrogesterone outperformed sustained-release micronized hydroxyprogesterone, with positive pregnancy test rates of 83% and 30%, respectively. The oral administration of dydrogesterone was well-tolerated and demonstrated a safety profile similar to sustained-release micronized hydroxyprogesterone.

The results highlighted the effectiveness of dydrogesterone over sustained-release micronized hydroxyprogesterone for luteal phase support in infertility treatment. Dydrogesterone exhibited superior positive pregnancy rates, making it a commendable choice in reproductive medicine. 

The unique pharmacological attributes of dydrogesterone, devoid of estrogenic, androgenic, or glucocorticoid effects, emphasize its suitability for assisted reproduction. The authors stated that dydrogesterone is a promising asset in enhancing successful outcomes in infertility treatment – suggesting its consideration as a valuable adjunctive therapy during the luteal phase.

Source: Vellanki J, Sravani E. Indian J ObstetGynecol Res. 2023;10(4):456-459